CD4 and myeloid sarcoma: The rationale underlying this approach lies in the augmented production of regulatory cytokines by T cells, attributed to the absence of the β2-domain of MHC-II molecules, which typically houses the CD4 coreceptor binding site.429 EAE models have demonstrated that RTL therapy effectively prevents and reverses EAE pathology, diminishes the severity of CNS lesions, and promotes neuronal regeneration.430–433 In 2012, a phase I dose-escalation study involving a cohort of 34 HLA-DR2 MS patients was conducted.